Document is current
Any future updates will be listed below
-
Authors
Xue, Yonger https://orcid.org/0000-0002-6022-2487
Zhang, Yuebao https://orcid.org/0009-0000-7883-1937
Zhong, Yichen
Du, Shi
Hou, Xucheng
Li, Wenqing
Li, Haoyuan
Wang, Siyu
Wang, Chang
Yan, Jingyue
Kang, Diana D.
Deng, Binbin
McComb, David W. https://orcid.org/0000-0003-3763-9652
Irvine, Darrell J. https://orcid.org/0000-0002-8637-1405
Weiss, Ron https://orcid.org/0000-0003-0396-2443
Dong, Yizhou https://orcid.org/0000-0001-5786-0659
- License Information
-
More Information
Article History
Received: 7 May 2023
Accepted: 15 January 2024
First Online: 25 January 2024
Change Date: 2 July 2026
Change Type: Update
Change Details: In the initially published version of this article, incorrect data were inadvertently included in Source Data Fig. 5, Fig. S4, Fig. S6 and Fig. S12 during data transfer. Only the presentation of Fig. S6b is affected. The Source Data and figure have now been amended in the HTML and PDF versions of the article.
Competing interests
: Y.X., Y.Zhang., D.J.I., R.W., and Y.D. are inventors on a patent application (63/433,109) filed by The Ohio State University and Massachusetts Institute of Technology. The patent covers engineered ASCs and their uses in this work. Y.D. is a scientific advisory board member and holds equity in Arbor Biotechnologies and Sirnagen Therapeutics. Y.D. is a co-founder and holds equity in Immunanoengineering Therapeutics. D.J.I. and R.W. are scientific advisory board members and hold equity in Strand Therapeutics. Other authors declare no conflict of interest.
